Participation of the C-terminal propeptide procollagen type I in the formation of cardiofibrosis in patients with myocardial infarction with preserved left ventricular ejection fraction

Aim. To study the dynamics of procollagen type I carboxy-terminal propeptide (PICP) with an assessment of potential associations with cardiac fibrosis (CF) and diastolic dysfunction (DD) of the left ventricle (LV) during the hospitalization and one year after ST segment elevation myocardial infarction (STEMI).

Material and methods. The study included 120 patients with STEMI. There were following inclusion criteria: diagnosis of STEMI (2015 European Society of Cardiology guidelines); Killip £III acute heart failure (AHF); signed informed consent; patient age >18 years old. There were following exclusion criteria: STEMI due to percutaneous coronary intervention or coronary artery bypass grafting; Killip IV AHF; patient age >80 years; clinically significant comorbidities; death of the patient during the first day of hospitalization. On the 1st, 12th day of the disease and after a year all patients underwent echocardiography and the PICP concentration was determined. One year after myocardial infarction, contrast-enhanced cardiac magnetic resonance imaging was performed to assess CF. In the analyzed group of patients, on day 1 of STEMI, mean values of LV ejection fraction (EF) in the range of 40-49% were observed in 3 (2,5%) patients, LVEF <40% — in 31 (26%), LVEF ≥50% — in 86 (71,7%). The final analysis was performed on a sample of patients with preserved LVEF (n=86) (71,7%).

Results. On the first day of myocardial infarction, signs of DD were noted in 25 (29,1%) patients, while after 1 year, their number increased by 9 (10%) and amounted to 34 (39,5%) patients. In 15 (17,6%) people, worsening of myocardial systolic dysfunction was noted. Patients with a CF ³16% had the highest PICP expression on the first day of the disease. CF ≥16% one year after STEMI with preserved EF is associated with PICP concentration on day 1 of the disease. In addition, multidirectional correlations were revealed between the CF ≥16% and parameters of LV diastolic function (e’, mean pulmonary artery pressure, E/e’).

Conclusion. Determination of the PICP concentration on the 1st day of myocardial infarction will allow early identification of patients at risk of CF one year after STEMI with preserved EF.

1. GBD 2017 Causes of Death Collaborators. Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018;392(10159):1736-88. doi: 10.1016/S0140-6736(18)32203-7.

2. Ferreira JP, Krausy S, Mitchellz S, et al. World Heart Federation Roadmap for Heart Failure. GLOBAL HEART. 2019;14(3):197-214. doi:10.1016/j.gheart.2019.07.004.

3. Jin L, Zhang J, Deng Z, et al. Mesenchymal stem cells ameliorate myocardial fibrosis in diabetic cardiomyopathy via the secretion of prostaglandin E2. Stem Cell Research & Therapy. 2020;11:122. doi:10.1186/s13287-020-01633-7.

4. Miklishanskaya SV, Mazur NA, Shestakova NV. Mechanisms for the formation myocardial fibrosis in norm and in certain cardiovascular diseases, how to diagnose it. Meditsinskiy sovet. 2017;12:75-81. (In Russ.) doi:10.21518/2079-701X-2017-12-75-81.

5. Leask A. Getting to the heart of the matter: new insights into cardiac fibrosis. Circ Res. 2015;116(7):1269-76. doi:10.1161/CIRCRESAHA.116.305381.

6. Humeres C, Frangogiannis NG. Fibroblasts in the Infarcted, Remodeling, and Failing Heart. JACC: Basic to Translational Science. 2019;24;4(3):449-67. doi:10.1016/j.jacbts.2019.02.006.

7. Barbarash OL, Gruzdeva OV, Pecherina TB, et al. Predictors of myocardial fibrosis and loss of epicardial adipose tissue volume in the long-term period after myocardial infarction. Russian Journal of Cardiology. 2020;25(2):3474. (In Russ.) doi:10.15829/1560-40712020-2-3474.

8. Mareev VYu, Fomin IV, Ageev FT, et al. Russian Heart Failure Society, Russian Society of Cardiology. Russian Scientific Medical Society of Internal Medicine Guidelines for Heart failure: chronic (CHF) and acute decompensated (ADHF). Diagnosis, prevention and treatment. Kardiologiia. 2018;58(6S):8-158. (In Russ.) doi:10.18087/cardio.2475.

9. Mrikaev DV. Left ventricular diastolic dysfunction in patients with heart failure. Creative cardiology. 2017;11(2):145-58. (In Russ.) doi:10.24022/1997-31872017-11-2-145-158.

10. Loffredo FS, Nikolova AP, Pancoast JR, Lee RT. Heart Failure With Preserved Ejection Fraction Molecular Pathways of the Aging Myocardium. Circ Res. 2014;115:97-107. doi:10.1161/CIRCRESAHA.115.302929.

11. Shiliaeva NV, Shchukin IUV, Limareva LV, Danilchenko OP. Biomarkers of myocardial stress and fibrosis in determining clinical outcomes in patients with heart failure who have suffered a myocardial infarction. Russian Journal of Cardiology. 2018;1(153):32-6. (In Russ.) doi:10.15829/1560-4071-2018-1-32-36.

12. Drapkina ОМ, Zyatenkova ЕV. Fibrosis markers in metabolic syndrome. Russian medical journal. 2016;26:1727-31. (In Russ.)

13. Kokov АN, Masenko VL, Semenov SE, Barbarash OL. Cardiac MRI in evaluation postinfarction changes and its role in determining the revascularization tactics. Complex Issues of Cardiovascular Diseases. 2014;(3):97-102. (In Russ.) doi:10.17802/2306-1278-20143-97-102.

14. Frangogiannis NG. Cardiac fibrosis: Cell biological mechanisms, molecular pathways and therapeutic opportunities. Mol Aspects Med. 2019;65:70-99. doi:10.1016/j.mam.2018.07.001.